- Home
- EOS vs COGT Comparison
EOS vs COGT Comparison
Compare EOS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOS
- COGT
- Stock Information
- Founded
- EOS 2005
- COGT 2014
- Country
- EOS United States
- COGT United States
- Employees
- EOS N/A
- COGT N/A
- Industry
- EOS Trusts Except Educational Religious and Charitable
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- EOS Finance
- COGT Health Care
- Exchange
- EOS Nasdaq
- COGT Nasdaq
- Market Cap
- EOS 1.3B
- COGT 1.1B
- IPO Year
- EOS N/A
- COGT 2018
- Fundamental
- Price
- EOS $24.20
- COGT $12.54
- Analyst Decision
- EOS
- COGT Strong Buy
- Analyst Count
- EOS 0
- COGT 11
- Target Price
- EOS N/A
- COGT $21.20
- AVG Volume (30 Days)
- EOS 84.1K
- COGT 1.5M
- Earning Date
- EOS 01-01-0001
- COGT 11-11-2025
- Dividend Yield
- EOS 6.80%
- COGT N/A
- EPS Growth
- EOS N/A
- COGT N/A
- EPS
- EOS N/A
- COGT N/A
- Revenue
- EOS N/A
- COGT N/A
- Revenue This Year
- EOS N/A
- COGT N/A
- Revenue Next Year
- EOS N/A
- COGT N/A
- P/E Ratio
- EOS N/A
- COGT N/A
- Revenue Growth
- EOS N/A
- COGT N/A
- 52 Week Low
- EOS $15.62
- COGT $3.72
- 52 Week High
- EOS $20.63
- COGT $13.50
- Technical
- Relative Strength Index (RSI)
- EOS 53.64
- COGT 55.83
- Support Level
- EOS $24.18
- COGT $12.28
- Resistance Level
- EOS $24.49
- COGT $13.13
- Average True Range (ATR)
- EOS 0.20
- COGT 0.50
- MACD
- EOS 0.03
- COGT -0.07
- Stochastic Oscillator
- EOS 67.58
- COGT 41.10
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.